Comparing the current results to its competitors, Vertex Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 12.45 % year on year. The sales growth was above Vertex Pharmaceuticals Inc's competitors' average revenue growth of 5.45 %, achieved in the same quarter.
Vertex Pharmaceuticals Inc Net Income in the 2 quarter 2026 grew year on year by 6.48%, while most of its competitors have experienced a contraction in net income by -83.82 %.
October 17, 2025
As Vertex Pharmaceuticals continues its path of innovation and alignment with cutting-edge medical advancements, the company recently announced significant progress across its development program for povetacicept. This investigational recombinant fusion protein therapeutic is positioned as a dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Povetacicept, also referred to by its abbreviation pove, has shown considerable promise in the treatment of IgA nephropathy (IgAN) and primary membranous nephropathy (pMN), two challenging kidney disorders.Vertex s ambition with povetacicept goes beyond its initial potential, showing promise as a “pipeline-in-a-pro...
March 29, 2025
As the landscape of pharmaceutical innovation continues to evolve, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) stands at the forefront, making significant strides in the treatment of complex genetic disorders such as Type 1 Diabetes (T1D) and Cystic Fibrosis (CF). In recent announcements, Vertex has provided valuable updates regarding their ongoing clinical studies and FDA approvals that transcend traditional therapeutic boundaries and pave the way for enhanced patient care.One of the most promising developments is the progress of the Phase 1/2 VX-264 study focused on Type 1 Diabetes. Vertex has successfully completed enrollment and dosing in both Parts A and B of this pioneering study aimed at addres...
December 20, 2024
Vertex Pharmaceuticals Expands Treatment Options for Cystic Fibrosis and Advances Pain Management Approaches BOSTON, MA Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has made significant strides in its commitment to improving the lives of individuals with cystic fibrosis (CF) and addressing acute pain through recent U.S. Food and Drug Administration (FDA) approvals and new drug applications (NDAs). This article delves into the details surrounding the approval of TRIKAFTA for additional cystic fibrosis variants and highlights developments in Vertex’s investigational drug pipeline, including suzetrigine for acute pain and vanzacaftor/tezacaftor/deutivacaftor for CF. Expanded Approval for TRIKAFTAVer...
July 30, 2024
In an epochal advancement for the pharmaceutical industry, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has heralded a pivotal moment marked by the U.S. Food and Drug Administration (FDA) acceptance of its New Drug Application (NDA) for suzetrigine a novel investigational drug poised to revolutionize the treatment of moderate-to-severe acute pain. This milestone underscores the promising future that suzetrigine, an oral, selective NaV1.8 pain signal inhibitor, envisions, particularly as it stands to become the first new class of medicine for acute pain treatment in over two decades. A Historic Advancement The FDA s acceptance of the NDA for suzetrigine is a testament to the drug s potential impact in a...
June 21, 2024
Vertex Pharmaceuticals: Achieving Breakthroughs in Diabetes and Cystic Fibrosis Treatments Boston-based Vertex Pharmaceuticals Incorporated, a company known for its innovative approach to tackling serious diseases, has recently made significant strides in the treatment of Type 1 Diabetes (T1D) and Cystic Fibrosis (CF). In two landmark presentations at the American Diabetes Association s 84th Scientific Sessions and the European Cystic Fibrosis Society s 47th European Cystic Fibrosis Conference, the company detailed promising data from its latest clinical trials. Transformative Potential in Type 1 DiabetesAt the American Diabetes Association s 84th Scientific Sessions, Vertex unveiled promising interim result...
June 14, 2024
CASGEVY: A Groundbreaking Treatment for Genetic Blood Disorders:Vertex s CASGEVY (exa-cel) has emerged as a groundbreaking therapy for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The long-term data presented at the EHA Congress confirmed the transformative and durable clinical benefits of CASGEVY over time. Notably, CASGEVY is the first and only approved treatment for these conditions, providing new hope for patients who face significant symptoms and diminished quality of life. With these promising results, Vertex is leading the charge in redefining the treatment paradigm for genetic blood disorders.TRIKAFTA: A Life-Changing Breakthrough for Cystic Fibrosis Patients:Ver...
May 6, 2024
Cystic Fibrosis (CF) is a genetic disorder that affects the respiratory and digestive systems, impacting the lives of millions of individuals worldwide. Vertex Pharmaceuticals, a renowned biotechnology company, has made significant strides in the treatment of CF. In two recent announcements, Vertex reported robust financial results for the first quarter of 2024 and received approval from the European Commission to expand the use of their drug, Kalydeco, to infants as young as one month old with specific CFTR gene mutations. This exciting development marks a crucial milestone in the battle against cystic fibrosis.Vertex s Financial Performance:Vertex Pharmaceuticals recorded impressive consolidated financial ...
April 28, 2024
LONDON - In a significant development for cystic fibrosis (CF) treatment, Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the European Commission (EC) has approved the use of KALYDECO (ivacaftor) for the treatment of infants as young as one month old affected by the disease. This landmark decision constitutes an expansion of the original labeling for KALYDECO, further validating the drug s potential in the battle against cystic fibrosis.Cystic Fibrosis is a genetic disorder affecting more than 70,000 people worldwide. It primarily impacts the lungs and digestive system, leading to severe respiratory and digestive problems. The disease is caused due to mutations in the cystic fibrosis transmembrane...
Publicly Traded Peers of Vertex Pharmaceuticals Inc
Cytokinetics Incorporated Share Performance
+17.80%
This Year
Cytokinetics Incorporated
Profile
Cytokinetics Incorporated is a biopharmaceutical company with a business model centered around the discovery and development of novel muscle activators. They strive to improve the lives of patients with debilitating diseases by focusing on the development of potentially life-changing therapies. Cytokinetics aims to achieve commercial success by leveraging its expertise in muscle biology and utilizing strategic collaborations to bring their innovative therapies to market.
Igm Biosciences Inc's business model focuses on the discovery and development of engineered Immunoglobulin M (IgM) antibodies to treat various diseases, primarily cancer.
Repare Therapeutics Inc is a biotechnology company that specializes in the development of precision oncology drugs. Their business model focuses on leveraging synthetic lethality, a targeted therapy approach, to identify and develop small molecule drugs for the treatment of various forms of cancer. By discovering and advancing novel therapeutics, Repare Therapeutics aims to improve patient outcomes and address unmet medical needs in oncology.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Sources:
Vertex Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vertex Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
